Law360, New York (June 17, 2015, 8:28 PM EDT) -- Venture capital-backed Nivalis Therapeutics Inc. roared onto the market Wednesday after topping expectations for its initial public offering, making it the latest life sciences company to spark investor interest as a robust acquisition environment adds fuel to the red-hot IPO market.
Nivalis, which is developing a treatment for cystic fibrosis, raised $77 million after pricing 5.5 million shares — 1 million more than expected — at $14 each, the midpoint of its targeted range, the company said. Shares opened on the Nasdaq under the symbol NVLS Wednesday, kicking off trading at $16.50 each before closing at a more modest $14.92, representing a...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!